

Muhammad Furqan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8682844/publications.pdf>

Version: 2024-02-01

30
papers

1,571
citations

706676

14
h-index

563245

28
g-index

32
all docs

32
docs citations

32
times ranked

3209
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer. <i>Redox Biology</i> , 2022, 53, 102318.	3.9	8
2	Magnetic resonance imaging (MRI) of pharmacological ascorbate-induced iron redox state as a biomarker in subjects undergoing radio-chemotherapy. <i>Redox Biology</i> , 2021, 38, 101804.	3.9	14
3	Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer. <i>BMC Cancer</i> , 2021, 21, 808.	1.1	43
4	Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation. <i>Translational Lung Cancer Research</i> , 2021, 10, 3608-3615.	1.3	5
5	Time to put it out “ nurse-facilitated tobacco treatment in a comprehensive cancer center. <i>Translational Behavioral Medicine</i> , 2021, 11, 1726-1738.	1.2	0
6	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 3713-3736.	1.3	12
7	Narrative review: mesenchymal-epithelial transition inhibitors“meeting their target. <i>Translational Lung Cancer Research</i> , 2021, 10, 462-474.	1.3	6
8	The clinical significance of soluble PD-1 and PD-L1 in lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 148-152.	2.0	60
9	Comparing high-dose cisplatin with cisplatin-based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC). <i>Cancer Medicine</i> , 2019, 8, 2730-2739.	1.3	9
10	Association of Hemophagocytic Lymphohistiocytosis and Programmed Death 1 Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2019, 14, e77-e78.	0.5	14
11	Lobar versus sub-lobar surgery for pulmonary typical carcinoid, a population-based analysis. <i>Journal of Thoracic Disease</i> , 2018, 10, 5850-5859.	0.6	17
12	Screening Patients with Esophageal Cancer to Determine Eligibility for Adjuvant Treatment Trials. <i>Anticancer Research</i> , 2018, 38, 5247-5251.	0.5	0
13	Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti“PD-L1 Immunotherapy Be Administered after Anti“PD-1“Related Immune Toxicities?. <i>Journal of Thoracic Oncology</i> , 2018, 13, e102-e103.	0.5	11
14	O ₂ and H ₂ O ₂ -Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. <i>Cancer Cell</i> , 2017, 31, 487-500.e8.	7.7	316
15	Mitochondrial Superoxide Increases Age-Associated Susceptibility of Human Dermal Fibroblasts to Radiation and Chemotherapy. <i>Cancer Research</i> , 2017, 77, 5054-5067.	0.4	31
16	A Single-Institution Analysis of Thymic Carcinoma Treated with Multi-Modality Therapy. , 2017, 1, .		0
17	The Conundrum of “Warfarin Hypersensitivity“: <i>American Journal of Therapeutics</i> , 2016, 23, e911-e915.	0.5	4
18	Air leakage in multiple compartments after endoscopy. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, 705-707.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Novel ALK inhibitors in clinical use and development. <i>Journal of Hematology and Oncology</i> , 2015, 8, 17.	6.9	81
20	Germline mutations predisposing to non-small cell lung cancer. <i>Familial Cancer</i> , 2015, 14, 463-469.	0.9	15
21	Novel agents for advanced pancreatic cancer. <i>Oncotarget</i> , 2015, 6, 39521-39537.	0.8	29
22	Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock. <i>Frontiers of Medicine</i> , 2014, 8, 254-258.	1.5	0
23	Ibrutinib and Indolent B-Cell Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 253-260.	0.2	14
24	Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. <i>Journal of Hematology and Oncology</i> , 2013, 6, 88.	6.9	211
25	STAT inhibitors for cancer therapy. <i>Journal of Hematology and Oncology</i> , 2013, 6, 90.	6.9	157
26	Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. <i>Biomarker Research</i> , 2013, 1, 5.	2.8	146
27	MEK and the inhibitors: from bench to bedside. <i>Journal of Hematology and Oncology</i> , 2013, 6, 27.	6.9	219
28	APACHE II scores as predictors of cardio pulmonary resuscitation outcome: Evidence from a tertiary care institute in a low-income country. <i>Saudi Journal of Anaesthesia</i> , 2012, 6, 31.	0.2	8
29	Miliary Pattern on Chest Radiography: TB or not TB?. <i>Mayo Clinic Proceedings</i> , 2010, 85, 108.	1.4	13
30	Cardiopulmonary resuscitation: outcome and its predictors among hospitalized adult patients in Pakistan. <i>International Journal of Emergency Medicine</i> , 2008, 1, 27-34.	0.6	20